11th International VHL Symposium, October 23 rd 25 th, 2014.

Transcription

1 11th International VHL Symposium, October 23 rd 25 th, Scientific Meeting Date: October 23rd 24th, 2014 Venue: Auditorium Ernest Lluch. Melchor Fernández Almagro, Madrid; Families s day Date: October 25th, 2014 Venue: Aula Magna. Fundación Jiménez Díaz. Avda. Reyes Católicos, Madrid AGENDA Wednesday, October 22 nd p.m. Registration at the Hotel AC Cuzco Thursday, October 23 rd 8.00 Bus to the CNIO (for those attendees hosted at the Hotel AC Cuzco) 8.00 Registration (at the Auditorium Ernest Lluch) 8.45 Welcome Mercedes Robledo 9.00 Opening Lecture Basic and clinical research in pheochromocytoma: a winning combination Karel Pacak National Institutes of Health, Bethesda, United States Session 1 New insight from OMIC approaches 9.30 Metabolomic profiling Othon Iliopoulos Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, United States

2 9.55 Suppression of the Transcriptional Coactivator PGC 1 alpha Drives Metabolic Reprogramming and Tumor Growth in Renal Cell Carcinoma Amato Giaccia Department of Radiation Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California, United States Genetic studies of CHL and related disorders: impact of Next Generation Sequencing. Eamonn R Maher Department of Medical Genetics, University of Cambridge, United Kingdom Transcript omics in VHL disease and renal cell carcinoma Rathmell WK Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States Coffee Break Session 2: The Cilia Centrosome cycle and VHL Role of VHL in Ciliogenesis Wilhelm Krek Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland Aurora kinase and VHL in kidney cancer Yannick Arlot Institut de Génétique et Developpement de Rennes, Rennes, France Session 1. Short oral presentations Identification of molecular drivers of human hemangioblastoma Mianen Sun University of Texas MD Anderson Cancer Center, United States Role of mutant von Hippel Lindau on angiogenesis Alexandra Arreola University of North Carolina at Chapel Hill, United States

3 13.00 L 2 Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer Sunil Sudarshan Urology, University of Alabama at Birmingham; United States Next Generation Sequencing allows the identification of VHL mosaicism: study of a panel of 16 patients Pascal Pigny CHRU Lille, France Lunch and poster view Session 3. Diagnosis, prognostic markers and management of VHL Diagnosis and Clinical management of VHL disease Giuseppe Opocher Veneto Institute of Oncology, Padova, Italy Molecular pathogenesis of a new syndrome of Pheo/Paraganglioma, somatostatinoma and Polycythemia with HIF2 alpha mutation Zhengping Zhuang Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States Pathology of VHL disease Alexander Vortmeyer Yale University School of Medicine, New Haven, United States Session 2. Short oral presentations A comprehensive study of germline mutations in the VHL gene reveals the importance of precisely tuned dysregulation of the hypoxia pathway in oncogenesis. Betty Gardie Ecole Pratique des Hautes Etudes, Villejuif, France

4 Gallium DOTATATE PET/CT detects primary neuroendocrine tumors and metastases in patients with von Hippel Lindau Samira Sadowski National Institutes of Health, Bethesda, United States Coffee Break Screening and diagnostic aspects of Endolymphatic Sac Tumors ELSTs Marie Louise Mølgaard Binderup. Dept. of Cellular and Molecular Medicine, University of Copenhagen, Denmark Pheochromocytoma and pregnancy in VHL patients Jacques Lenders Radboud University Medical Center Nijmegen, The Netherlands Genetic counseling on VHL Ignacio Blanco Genetic Counseling and Clinical Genetics Program. Germans Trias Hospital, Barcelona, Spain Session 3. Short oral presentations Von Hippel Lindau disease in childhood: a retrospective French series. Caroline Abadie AP HP, Hôpital Bicêtre, France Long term prognosis of resected pancreatic neuroendocrine tumors in von Hippel Lindau disease is favorable and not influenced by small tumors left in place Louis de Mestier Hôpital Robert Debré, Reims, France Bus to the Hotel Dinner

5 8.00 Bus to the CNIO (for those attendees hosted at the Hotel AC Cuzco) Friday, October 24th Session 4. Current therapeutic scenario: from the animal models to the patient 8.45 State of the art of the therapeutic approaches Eric Jonasch Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States 9.10 A zebrafish model to study and therapeutically manipulate hypoxia signaling in tumorigenesis Rachel Giles University Medical Center Utrecht, The Netherland 9.35 Mouse models of cooperative tumour suppression in clear cell renal cell carcinoma Ian Frew Institute of Physiology, University of Zurich, Zurich, Switzerland Session 4. Short oral presentations Development of new experimental models for VHL disease by using patientderived ips cells. Eijiro Nakamura Medical Innovation Center, Kyoto University Graduate School of Medicine, Japan Correction of folding defects of oncogenic pvhl by small molecules leads to restoration of its function in vitro and to development of a corresponding animal model for the disease Daniel Segal Tel Aviv University, Israel Conditional inactivation of the mouse von Hippel Lindau tumor suppressor gene results in wide spread hyperplastic, inflammatory, and fibrotic lesions in the kidney Tien Hsu Boston University School of Medicine, United States Coffee Break

6 11.15 Cutting edge in systemic treatments of neuroendocrine tumours Jaume Capdevila Hospital Vall d'hebron, Barcelona, Spain Therapeutic markers of antiangiogenic drugs Cristina Rodríguez Antona Hereditary Endocrine Cancer Group, CNIO, Madrid, Spain Therapeutic challenges in ocular involvement José García Arumi Department of Ophthalmology, Hospital Valle de Hebrón, Barcelona, Spain Session 5. Short oral presentations Functional imbalances in chromatin modifiers as novel targets in Renal Carcinomas. Abhishek Chakraborty Dana Farber Cancer Institute, Boston, United States Exploiting synthetic lethality in kidney cancer to target the loss of the von Hippel Lindau tumor suppressor gene Sandra Turcotte Université de Moncton, New Brunswick, Canada Lunch and poster view Session 5. Challenges in surgery of VHL patients (talks: 20 minutes + 5 for discussion) Therapy for sporadic and von Hippel Lindau related hemangioblastomas of the central nervous system Sven Gläsker Department of Neurosurgery, Freiburg University Medical Center, Freiburg, Germany

7 14.55 Neurosurgery management of hemangioblastomas in difficult locations: Brain stem and spinal root hemangioblastomas role por neuronavegation and intraoperative neurophysiological monitoring José María de Campos Department of Neurosurgery, VHL Unit Care, Fundación Jiménez Díaz, Madrid, Spain Radiosurgery in CNS hemangioblastomas. When and how? Mª Elena Kusak Department of Neurosurgery, Radiosurgery Unit, Hospital Ruber Internacional, Madrid, Spain Session 6. Short oral presentations Therapeutic strategies for central nervous system hemangioblastomas in von Hippel Lindau disease Hiroshi Kanno Yokohama City University, Japan Quantitative image analysis indicates spatial niche formation but not malignant progression as driving force for intratumoral heterogeneity in clear cell renal cell carcinoma Stefan Duensing University of Heidelberg, Germany Coffee Break Minimally Invasive Surgery for Pheochromocytomas and Retroperitoneal Paragangliomas Martin K. Walz Kliniken Essen Mitte, Klinik für Chirugie und Zentrum für Minimal Invasive Chirugie, Essen, Germany Surgery for EndolymphaticSac Tumors (ELST) and auditory rehabilitation Carlos Cenjor Fundación Jiménez Díaz, Madrid, Spain Challenges in RCC surgery Jean Jacques Patard CHU, Bicêtre, France

8 Session 7. Short oral presentations Mesonephric Carcinogenesis in VHL Disease Samuel Sommaruga Yale University, New Haven, United States Percutaneous ablation of renal tumors in von Hippel Lindau disease Jean Michel Correas AP HP, Hôpital Bicêtre, Le Kremlin Bicêtre, France Bus to the Hotel Saturday, October 25th 8.00 Bus to the Fundación Jiménez Díaz (for those attendees hosted at the Hotel AC Cuzco) Registration at the Fundación Jiménez Díaz. There will be available simultaneous translation English Spanish Inauguración de la jornada y bienvenida (Welcome). Carmen Ayuso Department of Genetics, FJD Chair of the IIS Fundación Jiménez Díaz, UAM, Madrid, Spain 9.15 La enfermedad de VHL explicada a las familias (The VHL disease explained to the families) Karina Villar SESCAM. Health Service of Castilla La Mancha, Toledo, Spain Vicepresident of Alianza Española VHL 9.45 La experiencia en una Unidad de Tratamiento Integral VHL española (The experience of a Spanish VHL Care Unit) José M. de Campos Department of Neurosurgery, VHL Care Unit, IIS Fundación Jiménez Díaz, Madrid, Spain

9 10.00 El punto de vista de dos pacientes VHL (The point of view of two VHL patients) Fernando Mora Serna Paula Piqueres Valenciano Manejando las emociones del paciente VHL. Actividad interactiva con pacientes dirigida por un psicólogo clínico. (Dealing with Emotions of VHL Patient. Interactive activity with patients conducted by a psychologist) Roberto Álvarez Fundación Instituto San José. Hermanos de San Juan de Dios, Madrid, Spain Break VHLA s Cancer in our Gene International Patient Databank. Ilene Sussman VHL Family Alliance, EEUU Alianza Española VHL: trabajando juntos para encontrar una cura (Spanish Alliance: Working together to find a cure) Susi Martínez President of the Spanish Alliance VHL, Spain Clausura del Simposio (Closure of the Symposium and Farewell) José M. de Campos Department of Neurosurgery, VHL Care Unit, IIS Fundación Jiménez Díaz, Madrid, Spain Cocktail Lunch